A high A1C tells you blood sugar was high. It doesn't tell you why — and the why determines what happens next.
Every three to six months, millions of people with type 2 diabetes go in for a blood draw that produces a single number: their A1C. If it's above target, the conversation goes one of two ways. Either the doctor adjusts the medication, or they tell the patient they need to try harder with diet and exercise. Sometimes both.
What almost never happens is the conversation that actually matters: were you taking the medication consistently?
A high A1C and a patient who skipped doses three weeks out of every month is a completely different clinical situation from a high A1C in a patient with near-perfect adherence. The first problem is behavioral. The second is pharmacological — the drug may need adjusting, or switching, or augmenting. Making the right call requires knowing which situation you're in. And you can't know that from an A1C number alone.
Hemoglobin A1C — commonly abbreviated as A1C or HbA1c — is a blood test that measures the percentage of hemoglobin molecules in your red blood cells that have glucose attached to them. Because red blood cells live for approximately 90 to 120 days, A1C reflects average blood glucose over roughly that same window. It's often described as a "three-month average blood sugar" — which is a useful simplification, though the math is weighted toward more recent weeks.
An A1C below 5.7% is generally considered normal. Between 5.7% and 6.4% indicates prediabetes. At 6.5% or above, the diagnostic threshold for type 2 diabetes is met. For people already diagnosed and being treated, most endocrinologists target an A1C below 7.0%, though individual targets vary based on age, other health conditions, and risk of hypoglycemia.
The A1C test is extremely useful. It removes the variability of daily glucose readings — a single blood sugar measurement can be thrown off by a meal, stress, or illness, but A1C smooths across three months and gives a more stable signal. It's also a strong predictor of diabetes complication risk: higher sustained A1C correlates with higher risk of retinopathy, nephropathy, and cardiovascular disease over time.
A1C tells you that average blood glucose was elevated over the past three months. It does not tell you: whether that was caused by missed doses, whether the medication was taken consistently and simply isn't working well enough, whether blood sugar was uniformly elevated or highly variable with spikes and dips, or what happened in daily life during those three months that may have contributed. That context is what transforms a number into a useful clinical decision.
When a patient presents with an A1C above their target, there are two fundamentally different explanations — and they lead to completely different clinical responses.
If a patient is prescribed metformin twice daily but consistently skips their evening dose, or misses medication several days per week due to a chaotic schedule, their A1C will reflect the uncontrolled glucose those missed doses allowed. From the outside, this looks exactly like treatment failure — the A1C is high despite the patient being on medication.
The appropriate response here is not to add a second medication or increase the dose. The appropriate response is to understand why adherence is failing. Is the timing inconvenient? Does the patient have side effects they haven't reported? Are they unclear on why the medication matters? Are there cost barriers? Addressing the adherence problem is more effective, safer, and less expensive than escalating a regimen the patient is already struggling to maintain.
If a patient has been taking their diabetes medication faithfully — same time every day, no missed doses, consistent for months — and their A1C is still above target, that's a genuinely different clinical signal. It may mean the dose needs adjusting. It may mean the medication class isn't the right fit for this patient's physiology. It may mean a second agent is warranted. It may also prompt a deeper look at diet, activity, stress, or sleep — lifestyle factors that affect insulin sensitivity regardless of medication.
This is the scenario where escalation is appropriate. But rushing to escalation without knowing whether the medication was actually taken is a clinical shortcut that can result in patients on increasingly complex regimens when the real issue is that nobody asked whether they were taking what they already had.
Most clinical encounters with elevated A1C implicitly assume the patient was adherent. Doctors rarely have access to actual adherence data — so they make decisions based on the lab number and self-report. Self-report is unreliable: patients underreport missed doses, sometimes unconsciously, because the question feels evaluative. Without objective adherence data, the clinical picture is incomplete — and escalation decisions are made in the dark.
The structural reality is that A1C and medication adherence have historically been tracked through completely separate systems — when adherence is tracked at all.
A1C comes from the lab. It lives in the patient portal as a test result. Medication adherence, if it's tracked, might live in a pharmacy refill record — but refill records tell you when medication was picked up, not whether it was taken. Many patients keep their medication schedule entirely in their own heads, or in a paper weekly pill organizer, or in a reminder app that logs nothing.
Even when a patient is highly motivated and organized, these two data streams are rarely in the same place at the same time in a form that's easy to compare. A patient might remember they had a rough stretch in June when they were traveling and missed doses, and mentally connect that to a higher A1C. But they can't quantify it, and they can't show it to their doctor in a way that makes the connection concrete.
The result is that endocrinology and primary care appointments typically involve: reviewing the current A1C, comparing it to the previous one, discussing what changed in the patient's diet or lifestyle, and making a medication decision — all without a clear picture of what the medication was actually doing during those three months, because that data doesn't exist in a usable form.
When medication adherence is tracked alongside A1C results — both quantitatively and over time — the clinical picture becomes substantially clearer.
Consider two patients, both presenting with an A1C of 8.2%:
Both patients have the same A1C. The appropriate next step for each is completely different. Patient A may need a dose adjustment, a different medication class, or a review of their diet and insulin sensitivity. Patient B needs support with adherence — understanding why doses are being missed, possibly simplifying the regimen to a once-daily option, addressing side effects, or reducing barriers to consistent use.
Without the adherence data, a clinician looking only at the A1C of 8.2% is guessing which situation they're in. With it, the picture is immediately interpretable.
Cureva tracks medication adherence as a core function — every logged dose, every reminder acknowledged, every missed dose flagged. Over weeks and months, this builds a quantitative adherence record: not just "did the patient take their medication" in a general sense, but what specific dates were missed, what patterns exist (weekends more than weekdays? Evenings more than mornings?), and how adherence has trended over time.
When a patient uploads their A1C lab results into Cureva, Eva — Cureva's personal AI health companion — reads the result and connects it to the adherence record from the corresponding period. If the A1C covers approximately the past three months, Eva correlates it with the three months of medication data she already has. If vitals like blood glucose readings are also logged, those are incorporated as well.
The output is an AI health brief: a longitudinal picture that shows, in plain language, what the A1C was, what medication adherence looked like over the same period, how blood glucose readings trended, and what patterns Eva identifies as worth raising with the patient's endocrinologist or primary care physician.
Instead of arriving with just an A1C number, bring: your adherence rate for the past 90 days (how many doses you actually took), any patterns in missed doses (specific times of day, days of week), your logged blood glucose readings over the same period, and any side effects or concerns you've noted in your check-in logs. Cureva's AI health brief compiles all of this so you can hand your doctor a complete picture, not just a lab result.
This doesn't replace the endocrinologist's judgment. It gives that judgment the data it needs to be accurate. The doctor who sees "A1C 8.2%, adherence rate 91%, consistent fasting hyperglycemia" makes a very different — and more appropriate — decision than one who sees only "A1C 8.2%."
Regardless of whether you use Cureva or another tracking method, the goal is the same: arrive at your diabetes appointment with both data streams available, not just one.
The most productive diabetes appointments happen when patients come prepared with their own data. It changes the dynamic from "the doctor reviews numbers" to "patient and doctor review the picture together."
Cureva is available starting September 16, 2026, with beta access opening September 15. Founding pricing is $5/month for your first year, $14.99/month after that. The AI health brief feature — which connects lab results, medication adherence, and vitals into a single longitudinal picture — is included in every plan.
Medical Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. A1C targets, medication decisions, and diabetes management plans should always be determined by a qualified healthcare provider based on your individual health history and circumstances. Cureva is a health tracking and AI companion tool — not a medical device — and does not provide medical advice, diagnosis, or treatment recommendations. Always follow your endocrinologist's or primary care physician's guidance regarding your diabetes management.
Cureva tracks every dose, reads your lab uploads, and builds the longitudinal health brief your doctor actually needs to make the right call.
See Pricing →